- Home
- HCM vs OGN Comparison
HCM vs OGN Comparison
Compare HCM & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- OGN
- Stock Information
- Founded
- HCM 2000
- OGN 1923
- Country
- HCM Hong Kong
- OGN United States
- Employees
- HCM N/A
- OGN N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- HCM Health Care
- OGN Health Care
- Exchange
- HCM Nasdaq
- OGN Nasdaq
- Market Cap
- HCM 2.8B
- OGN 2.5B
- IPO Year
- HCM N/A
- OGN N/A
- Fundamental
- Price
- HCM $15.97
- OGN $10.30
- Analyst Decision
- HCM
- OGN Hold
- Analyst Count
- HCM 0
- OGN 4
- Target Price
- HCM N/A
- OGN $18.00
- AVG Volume (30 Days)
- HCM 59.1K
- OGN 3.9M
- Earning Date
- HCM 08-07-2025
- OGN 10-30-2025
- Dividend Yield
- HCM N/A
- OGN 0.83%
- EPS Growth
- HCM N/A
- OGN N/A
- EPS
- HCM 0.53
- OGN 2.69
- Revenue
- HCM $602,197,000.00
- OGN $6,281,000,000.00
- Revenue This Year
- HCM $2.73
- OGN N/A
- Revenue Next Year
- HCM $17.33
- OGN $1.36
- P/E Ratio
- HCM $5.63
- OGN $3.60
- Revenue Growth
- HCM N/A
- OGN N/A
- 52 Week Low
- HCM $11.51
- OGN $8.01
- 52 Week High
- HCM $21.50
- OGN $22.42
- Technical
- Relative Strength Index (RSI)
- HCM 50.89
- OGN 65.22
- Support Level
- HCM $14.69
- OGN $8.95
- Resistance Level
- HCM $15.50
- OGN $9.64
- Average True Range (ATR)
- HCM 0.28
- OGN 0.33
- MACD
- HCM -0.01
- OGN 0.12
- Stochastic Oscillator
- HCM 69.15
- OGN 99.26
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.